KINE 101A
Alternative Names: KINE-101ALatest Information Update: 22 Jan 2026
At a glance
- Originator Kine Sciences
- Class Antirheumatics; Peptides
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic inflammatory demyelinating polyradiculoneuropathy
- Phase I Rheumatoid arthritis
- Preclinical Inflammatory bowel diseases; Non-alcoholic steatohepatitis
Most Recent Events
- 22 Jan 2026 Preclinical trials in Inflammatory bowel diseases in South Korea (unspecified route), prior to January 2026 (Kine sciences piepline, January 2026)
- 22 Jan 2026 Preclinical trials in Non-alcoholic steatohepatitis in South Korea (unspecified route), prior to January 2026 (Kine sciences piepline, January 2026)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in USA